Skip to main content
Top
Published in: Surgery Today 5/2021

01-05-2021 | Liver Resection | Original Article

Enhanced patterns on intraoperative contrast-enhanced ultrasonography predict outcomes after curative liver resection in patients with hepatocellular carcinoma

Authors: Ikuo Nakamura, Etsuro Hatano, Masaharu Tada, Yusuke Kawabata, Shinjiro Tamagawa, Ami Kurimoto, Hideaki Iwama, Kan Toriguchi, Hideaki Sueoka, Kenjiro Iida, Masahiro Yoshida, Takashi Nishimura, Hiroko Iijima

Published in: Surgery Today | Issue 5/2021

Login to get access

Abstract

Purpose

This study aimed to clarify what hepatocellular carcinoma (HCC) phenotype, as categorized by intraoperative contrast-enhanced ultrasonography (CEUS), showed a high risk of recurrence after hepatic resection.

Methods

Patients who underwent initial curative hepatectomy with intraoperative CEUS for a single HCC nodule were retrospectively assigned to three patterns of fine (FI), vascular (VA), and irregular (IR) according to the maximum intensity projection pattern based on intraoperative CEUS. Staining was performed for Ki-67, pyruvate kinase type M2 (PKM2), and vascular endothelial growth factor (VEGF) to assess the tumor proliferative activity, tumor glucose metabolism, and angiogenesis, respectively.

Results

Of 116 patients, 18, 50, and 48 were assigned to the FI, VA and IR patterns, respectively. IR patients demonstrated a significantly worse prognosis for both the recurrence-free survival (RFS) and overall survival (OS) (P = 0.0002, 0.0262, respectively) than did patients with other patterns. A multivariate analysis revealed an IR pattern in intraoperative CEUS to be an independent predictive factor for a poor RFS, and major hepatectomy and an IR pattern were independent predictive factors for a poor OS. An IR pattern was closely related to the tumor size (≥ 3.3 cm) and poor histological differentiation and showed a high Ki-67 index, low VEGF expression, and high PKM2 expression.

Conclusion

IR-pattern HCCs as classified by intraoperative CEUS may be associated with a higher risk of recurrence and worse outcomes in HCC patients after hepatic resection than other patterns.
Appendix
Available only for authorised users
Literature
1.
go back to reference Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.CrossRef Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.CrossRef
2.
go back to reference Teefey SA, Hildeboldt CC, Dehdashti F, Siegel BA, Peters MG, Heiken JP, et al. Detection of primary hepatic malignancy in liver transplant candidates: prospective comparison of CT, MR imaging, US, and PET. Radiology. 2003;226:533–42.CrossRef Teefey SA, Hildeboldt CC, Dehdashti F, Siegel BA, Peters MG, Heiken JP, et al. Detection of primary hepatic malignancy in liver transplant candidates: prospective comparison of CT, MR imaging, US, and PET. Radiology. 2003;226:533–42.CrossRef
3.
go back to reference Choi J, Lee JM, Sirlin CB. CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part II. Extracellular agents, hepatobiliary agents, and ancillary imaging features. Radiology. 2014;273:30–50.CrossRef Choi J, Lee JM, Sirlin CB. CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part II. Extracellular agents, hepatobiliary agents, and ancillary imaging features. Radiology. 2014;273:30–50.CrossRef
4.
go back to reference Maruyama H, Sekimoto T, Yokosuka O. Role of contrast-enhanced ultrasonography with sonazoid for hepatocellular carcinoma: evidence from a 10-year experience. J Gastroenterol. 2016;51:421–33.CrossRef Maruyama H, Sekimoto T, Yokosuka O. Role of contrast-enhanced ultrasonography with sonazoid for hepatocellular carcinoma: evidence from a 10-year experience. J Gastroenterol. 2016;51:421–33.CrossRef
5.
go back to reference Sato K, Tanaka S, Mitsunori Y, Mogushi K, Yasen M, Aihara A, et al. Contrast-enhanced intraoperative ultrasonography for vascular imaging of hepatocellular carcinoma: clinical and biological significance. Hepatology. 2013;57:1436–47.CrossRef Sato K, Tanaka S, Mitsunori Y, Mogushi K, Yasen M, Aihara A, et al. Contrast-enhanced intraoperative ultrasonography for vascular imaging of hepatocellular carcinoma: clinical and biological significance. Hepatology. 2013;57:1436–47.CrossRef
6.
go back to reference Postema M, Gilja OH. Contrast-enhanced and targeted ultrasound. World J Gastroenterol. 2011;17:28–41.CrossRef Postema M, Gilja OH. Contrast-enhanced and targeted ultrasound. World J Gastroenterol. 2011;17:28–41.CrossRef
7.
go back to reference Wilson SR, Jang HJ, Kim TK, Iijima H, Kamiyama N, Burns PN. Real-time temporal maximum-intensity-projection imaging of hepatic lesions with contrast-enhanced sonography. AJR Am J Roentgenol. 2008;190:691–5.CrossRef Wilson SR, Jang HJ, Kim TK, Iijima H, Kamiyama N, Burns PN. Real-time temporal maximum-intensity-projection imaging of hepatic lesions with contrast-enhanced sonography. AJR Am J Roentgenol. 2008;190:691–5.CrossRef
8.
go back to reference Sugimoto K, Moriyasu F, Kamiyama N, Metoki R, Yamada M, Imai Y, et al. Analysis of morphological vascular changes of hepatocellular carcinoma by microflow imaging using contrast-enhanced sonography. Hepatol Res. 2008;38:790–9.CrossRef Sugimoto K, Moriyasu F, Kamiyama N, Metoki R, Yamada M, Imai Y, et al. Analysis of morphological vascular changes of hepatocellular carcinoma by microflow imaging using contrast-enhanced sonography. Hepatol Res. 2008;38:790–9.CrossRef
9.
go back to reference Kruskal JB, Kane RA. Intraoperative US of the liver: techniques and clinical applications. Radiographics. 2006;26:1067–84.CrossRef Kruskal JB, Kane RA. Intraoperative US of the liver: techniques and clinical applications. Radiographics. 2006;26:1067–84.CrossRef
10.
go back to reference Zhou YT, Cai WW, Li Y, Jiang X, Feng L, Zhu QY, et al. Correlations between quantitative parameters of contrast-enhanced ultrasound and vasculogenic mimicry in murine tumor model: a novel noninvasive technique for assessment? Biol Proc Online. 2019;21:11.CrossRef Zhou YT, Cai WW, Li Y, Jiang X, Feng L, Zhu QY, et al. Correlations between quantitative parameters of contrast-enhanced ultrasound and vasculogenic mimicry in murine tumor model: a novel noninvasive technique for assessment? Biol Proc Online. 2019;21:11.CrossRef
11.
go back to reference Cheng LG, He W, Zhang HX, Song Q, Ning B, Li HZ, et al. Intraoperative contrast enhanced ultrasound evaluates the grade of glioma. Biomed Res Int. 2016;2016:2643862.PubMedPubMedCentral Cheng LG, He W, Zhang HX, Song Q, Ning B, Li HZ, et al. Intraoperative contrast enhanced ultrasound evaluates the grade of glioma. Biomed Res Int. 2016;2016:2643862.PubMedPubMedCentral
12.
go back to reference Vraka I, Panourgias E, Sifakis E, Koureas A, Galanis P, Dellaportas D, et al. Correlation between contrast-enhanced ultrasound characteristics (qualitative and quantitative) and pathological prognostic factors in breast cancer. In Vivo. 2018;32:945–54.CrossRef Vraka I, Panourgias E, Sifakis E, Koureas A, Galanis P, Dellaportas D, et al. Correlation between contrast-enhanced ultrasound characteristics (qualitative and quantitative) and pathological prognostic factors in breast cancer. In Vivo. 2018;32:945–54.CrossRef
13.
go back to reference Kudo M, Kitano M, Sakurai T, Nishida N. General rules for the clinical and pathological study of primary liver cancer, nationwide follow-up survey and clinical practice guidelines: the outstanding achievements of the Liver Cancer Study Group of Japan. Digest Dis. 2015;33:765–70.CrossRef Kudo M, Kitano M, Sakurai T, Nishida N. General rules for the clinical and pathological study of primary liver cancer, nationwide follow-up survey and clinical practice guidelines: the outstanding achievements of the Liver Cancer Study Group of Japan. Digest Dis. 2015;33:765–70.CrossRef
14.
go back to reference Tanaka H, Iijima H, Higashiura A, Yoh K, Ishii A, Takashima T, et al. New malignant grading system for hepatocellular carcinoma using the sonazoid contrast agent for ultrasonography. J Gastroenterol. 2014;49:755–63.CrossRef Tanaka H, Iijima H, Higashiura A, Yoh K, Ishii A, Takashima T, et al. New malignant grading system for hepatocellular carcinoma using the sonazoid contrast agent for ultrasonography. J Gastroenterol. 2014;49:755–63.CrossRef
15.
go back to reference Lam CM, Fan ST, Lo CM, Wong J. Major hepatectomy for hepatocellular carcinoma in patients with an unsatisfactory indocyanine green clearance test. Br J Surg. 1999;86:1012–7.CrossRef Lam CM, Fan ST, Lo CM, Wong J. Major hepatectomy for hepatocellular carcinoma in patients with an unsatisfactory indocyanine green clearance test. Br J Surg. 1999;86:1012–7.CrossRef
16.
go back to reference Couinaud C. Liver lobes and segments: notes on the anatomical architecture and surgery of the liver. Presse Med. 1954;62:709–12.PubMed Couinaud C. Liver lobes and segments: notes on the anatomical architecture and surgery of the liver. Presse Med. 1954;62:709–12.PubMed
17.
go back to reference Hasegawa K, Kokudo N, Imamura H, Matsuyama Y, Aoki T, Minagawa M, et al. Prognostic impact of anatomic resection for hepatocellular carcinoma. Ann Surg. 2005;242:252–9.CrossRef Hasegawa K, Kokudo N, Imamura H, Matsuyama Y, Aoki T, Minagawa M, et al. Prognostic impact of anatomic resection for hepatocellular carcinoma. Ann Surg. 2005;242:252–9.CrossRef
18.
go back to reference Kitamura K, Hatano E, Higashi T, Narita M, Seo S, Nakamoto Y, et al. Proliferative activity in hepatocellular carcinoma is closely correlated with glucose metabolism but not angiogenesis. J Hepatol. 2011;55:846–57.CrossRef Kitamura K, Hatano E, Higashi T, Narita M, Seo S, Nakamoto Y, et al. Proliferative activity in hepatocellular carcinoma is closely correlated with glucose metabolism but not angiogenesis. J Hepatol. 2011;55:846–57.CrossRef
19.
go back to reference Watanabe R, Matsumura M, Chen CJ, Kaneda Y, Ishihara M, Fujimaki M. Gray-scale liver enhancement with sonazoid (NC100100), a novel ultrasound contrast agent; detection of hepatic tumors in a rabbit model. Biol Pharm Bull. 2003;26:1272–7.CrossRef Watanabe R, Matsumura M, Chen CJ, Kaneda Y, Ishihara M, Fujimaki M. Gray-scale liver enhancement with sonazoid (NC100100), a novel ultrasound contrast agent; detection of hepatic tumors in a rabbit model. Biol Pharm Bull. 2003;26:1272–7.CrossRef
20.
go back to reference Hagen EK, Forsberg F, Aksnes AK, Merton DA, Liu JB, Tornes A, et al. Enhanced detection of blood flow in the normal canine prostate using an ultrasound contrast agent. Investig Radiol. 2000;35:118–24.CrossRef Hagen EK, Forsberg F, Aksnes AK, Merton DA, Liu JB, Tornes A, et al. Enhanced detection of blood flow in the normal canine prostate using an ultrasound contrast agent. Investig Radiol. 2000;35:118–24.CrossRef
21.
go back to reference Takada H, Tsuchiya K, Yasui Y, Nakakuki N, Tamaki N, Suzuki S, et al. Irregular vascular pattern by contrast-enhanced ultrasonography and high serum lens culinaris agglutinin-reactive fraction of alpha-fetoprotein level predict poor outcome after successful radiofrequency ablation in patients with early-stage hepatocellular carcinoma. Cancer Med. 2016;5:3111–200.CrossRef Takada H, Tsuchiya K, Yasui Y, Nakakuki N, Tamaki N, Suzuki S, et al. Irregular vascular pattern by contrast-enhanced ultrasonography and high serum lens culinaris agglutinin-reactive fraction of alpha-fetoprotein level predict poor outcome after successful radiofrequency ablation in patients with early-stage hepatocellular carcinoma. Cancer Med. 2016;5:3111–200.CrossRef
22.
go back to reference Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000;182:311–22.CrossRef Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000;182:311–22.CrossRef
23.
go back to reference Kitamura K, Hatano E, Higashi T, Seo S, Nakamoto Y, Yamanaka K, et al. Preoperative FDG-PET predicts recurrence patterns in hepatocellular carcinoma. Ann Surg Oncol. 2012;19:156–62.CrossRef Kitamura K, Hatano E, Higashi T, Seo S, Nakamoto Y, Yamanaka K, et al. Preoperative FDG-PET predicts recurrence patterns in hepatocellular carcinoma. Ann Surg Oncol. 2012;19:156–62.CrossRef
24.
go back to reference Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov. 2007;6:273–86.CrossRef Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov. 2007;6:273–86.CrossRef
25.
go back to reference Kleespies A, Guba M, Jauch KW, Bruns CJ. Vascular endothelial growth factor in esophageal cancer. J Surg Oncol. 2004;87:95–104.CrossRef Kleespies A, Guba M, Jauch KW, Bruns CJ. Vascular endothelial growth factor in esophageal cancer. J Surg Oncol. 2004;87:95–104.CrossRef
26.
go back to reference Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res. 1995;55:3964–8.PubMed Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res. 1995;55:3964–8.PubMed
27.
go back to reference Yamaguchi R, Yano H, Iemura A, Ogasawara S, Haramaki M, Kojiro M. Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatology. 1998;28:68–77.CrossRef Yamaguchi R, Yano H, Iemura A, Ogasawara S, Haramaki M, Kojiro M. Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatology. 1998;28:68–77.CrossRef
28.
go back to reference Zacharoulis D, Hatzitheofilou C, Athanasiou E, Zacharoulis S. Antiangiogenic strategies in hepatocellular carcinoma: current status. Expert Rev Anticancer Ther. 2005;5:645–56.CrossRef Zacharoulis D, Hatzitheofilou C, Athanasiou E, Zacharoulis S. Antiangiogenic strategies in hepatocellular carcinoma: current status. Expert Rev Anticancer Ther. 2005;5:645–56.CrossRef
29.
go back to reference Spoden GA, Rostek U, Lechner S, Mitterberger M, Mazurek S, Zwerschke W. Pyruvate kinase isoenzyme M2 is a glycolytic sensor differentially regulating cell proliferation, cell size and apoptotic cell death dependent on glucose supply. Exp Cell Res. 2009;315:2765–74.CrossRef Spoden GA, Rostek U, Lechner S, Mitterberger M, Mazurek S, Zwerschke W. Pyruvate kinase isoenzyme M2 is a glycolytic sensor differentially regulating cell proliferation, cell size and apoptotic cell death dependent on glucose supply. Exp Cell Res. 2009;315:2765–74.CrossRef
30.
go back to reference Mazurek S, Boschek CB, Hugo F, Eigenbrodt E. Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin Cancer Biol. 2005;15:300–8.CrossRef Mazurek S, Boschek CB, Hugo F, Eigenbrodt E. Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin Cancer Biol. 2005;15:300–8.CrossRef
Metadata
Title
Enhanced patterns on intraoperative contrast-enhanced ultrasonography predict outcomes after curative liver resection in patients with hepatocellular carcinoma
Authors
Ikuo Nakamura
Etsuro Hatano
Masaharu Tada
Yusuke Kawabata
Shinjiro Tamagawa
Ami Kurimoto
Hideaki Iwama
Kan Toriguchi
Hideaki Sueoka
Kenjiro Iida
Masahiro Yoshida
Takashi Nishimura
Hiroko Iijima
Publication date
01-05-2021
Publisher
Springer Singapore
Published in
Surgery Today / Issue 5/2021
Print ISSN: 0941-1291
Electronic ISSN: 1436-2813
DOI
https://doi.org/10.1007/s00595-020-02145-w

Other articles of this Issue 5/2021

Surgery Today 5/2021 Go to the issue